MassDevice Q&A: John McDonough

August 4, 2009 by Joe Nowlan

The T2 Biosystems CEO on the company's innovative, miniaturized diagnostic tool, the importance of de-risking before you hit the fundraising trail and why the U.S. intelligence community is interested in T2's technology.

John McDonough, CEO of Cambridge, Mass.-based T2 Biosystems Inc., is an optimist.

Bullish on his 22-employee company's prospects (the estimated $40 billion diagnostics market might have something to do with that), McDonough (far left in the picture at right) spoke with MassDevice about the technology behind T2's diagnostic device, which uses a miniaturized version of a magnetic resonance imaging machine to deliver near-instant test results from just about any blood, urine or saliva sample.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Features

ResMed CEO Mick Farrell tells MassDevice.com about the history of ResMed, its sleep apnea devices and the future of treating chronic disease.

Dr. Robert Greenberg, founder & CEO of Second Sight Medical, chats with MassDevice.com in advance of his appearance at the Big 100 West to discuss the Argus II 'bionic eye.'

CEO Josh Kornberg tells MassDevice.com about cleaning house and how bad news for rival Stryker Corp. is helping to reinvigorate Skyline Medical.

In this MassDevice.com podcast, we speak with Glooko CEO Rick Altinger about the company's mobile diabetes management application for smartphones and how it has the potential to change the spectrum of care for one of the world's most common chronic diseases.

Renal denervation has won a lot of praise as a potential solution for patients with resistant hypertension, but the excessive celebration of early clinical trial results may be setting everyone up for a major letdown and a harsh backlash. This week cardiologists at the Transcatheter Cardiovascular Therapeutics conference, including those involved with Medtronic's and Boston Scientific's clinical trials, warned of the dangers of exaggeration.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp